Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,182 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Metabolic Assessment Clear all
Not yet recruiting Not applicable Interventional

Duke Cardiometabolic Prevention Clinic's Impact on High-risk Cardiovascular Patients With Uncontrolled Risk Factors

NCT07117695
View directory record Official record
Conditions
ASCVD, Hyperlipidemia, Hypertension
Interventions
Referral to the Duke Cardiometabolic Prevention Clinic
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

NCT00819403
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
simvastatin, ezetimibe/simvastatin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

NCT03965130
View directory record Official record
Conditions
Healthy Participants
Interventions
Glucagon, Control Study
Biological · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 19, 2026, 9:54 PM EDT
Not listed Not applicable Interventional

Lifestyle Intervention to Reduce Body Weight and Systemic Inflammation Among World Trade Center Responders

NCT05138198
View directory record Official record
Conditions
Post-Traumatic Stress Disorder, Overweight and Obesity, Metabolic Syndrome, Inflammation
Interventions
Mediterranean Diet & Physical Activity, Usual Care
Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
40 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Commack, New York
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Not applicable Interventional

Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients

NCT02551640
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Prediabetic State, Hypertension, Prehypertension, Obesity
Interventions
FeatForward App (on study smartphone)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Charlestown, Massachusetts • Revere, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 19, 2026, 9:54 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of RSB11-HI Postbiotic Supplementation for Supporting Weight Management, Metabolic Wellness, and Quality of Life in Healthy Adults

NCT07788833
View directory record Official record
Conditions
Healthy Adults
Interventions
RSB11-HI Heat-Inactivated Postbiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Able Biolabs, LLC
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 9:54 PM EDT
Recruiting Not applicable Interventional

Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

NCT07454174
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Ren-Nu and KetoCitra
Dietary Supplement
Lead sponsor
Richard Fatica
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD

NCT03490968
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Supervised Exercise, Vascular Assessment
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

NCT02229396
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exantide with Dapagliflozin, Exentide, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
76
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 19, 2026, 9:54 PM EDT
Not yet recruiting Phase 2 Interventional

Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma

NCT07790913
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission, Non-Hodgkin Lymphoma in Remission, Cancer Survivorship
Interventions
Phentermine/Topiramate ER, Health Behavior and Lifestyle Counseling
Drug · Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 24 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NCT04048135
View directory record Official record
Conditions
NASH
Interventions
Pegozafermin, Placebo
Drug · Other
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 19, 2026, 9:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Age Related Changes in Calciotropic Hormones and Their Impact on Male Osteoporosis

NCT00588874
View directory record Official record
Conditions
Low Bone Density
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
50 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Not applicable Interventional

A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19

NCT04414124
View directory record Official record
Conditions
Mild-to-moderate COVID-19
Interventions
KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
Other
Lead sponsor
Kaleido Biosciences
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Hot Springs, Arkansas • Riverside, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 19, 2026, 9:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

NCT00755313
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions
trastuzumab, aromatase inhibition therapy, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, metabolic assessment, questionnaire administration, study of socioeconomic and demographic variables, cognitive assessment, positron emission tomography, fludeoxyglucose F 18
Biological · Drug · Other + 2 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years to 80 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects

NCT01103726
View directory record Official record
Conditions
Healthy
Interventions
PF-02545920, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Phase 1 Interventional

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

NCT01212380
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions
carfilzomib, Cytokine Assessment, Pharmacodynamic Studies, Proteosome Inhibition Assessment, Pharmacogenomic Studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 19, 2026, 9:54 PM EDT
Suspended Not applicable Interventional

Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00433173
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 75 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 19, 2026, 9:54 PM EDT
Recruiting No phase listed Observational

DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins

NCT07298083
View directory record Official record
Conditions
Neurofibromas, MPNST
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 19, 2026, 9:54 PM EDT
Recruiting No phase listed Observational

Recovery Trajectory for Coma and Disorders of Consciousness

NCT07614074
View directory record Official record
Conditions
Coma, Disorders of Consciousness, Cardiac Arrest (CA), Traumatic Brain Injuries, Ischemic Stroke, Hemorrhagic Stroke, Intracerebral, Meningitis/Encephalitis, Status Epilepticus
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Not applicable Interventional

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar or Schizophrenia Illness

NCT03935854
View directory record Official record
Conditions
Obesity, Ketogenic Dieting, Metabolic Syndrome, Bipolar Disorder, Schizophrenia, Weight Gain, Psychotropic Agents Causing Adverse Effects in Therapeutic Use, Brain Metabolic Disorder
Interventions
LCHF, Ketogenic Diet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

NCT03406962
View directory record Official record
Conditions
Inherited Metabolic Disorders (IMD)
Interventions
MGTA-456
Drug
Lead sponsor
Magenta Therapeutics, Inc.
Industry
Eligibility
0 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 19, 2026, 9:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The HIV, Adipose Tissue Immunology, and Metabolism Study

NCT04451980
View directory record Official record
Conditions
Hiv, Diabetes Mellitus, Type 2
Interventions
Subcutaneous adipose tissue biopsy, CT scan, Oral glucose tolerance test, Blood collection
Procedure · Radiation · Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 19, 2026, 9:54 PM EDT
Recruiting Phase 2 Interventional

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07288138
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatohepatitis
Interventions
Placebo, ECC4703, ECC0509
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
68
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 9:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Exercise on Muscle Metabolism and Function for Persons With Parkinsons

NCT07720713
View directory record Official record
Conditions
Parkinson
Interventions
Home Exercise Program
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 9:54 PM EDT